Cameron Messier
YOU?
Author Swipe
View article: Atomistic TCR-ligand interactions instruct memory T-cell differentiation
Atomistic TCR-ligand interactions instruct memory T-cell differentiation Open
Summary Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation 1–4 . How naive CD8⁺ T ce…
View article: Orthosteric STING inhibition elucidates molecular correction of SAVI STING
Orthosteric STING inhibition elucidates molecular correction of SAVI STING Open
STING is broadly implicated in diseases ranging from cancer, autoimmune disease, neurodegeneration to rare, monogenic diseases. 1 Early drug discovery campaigns focused on STING activation as a promising platform for cancer immunotherapy y…
View article: Supplementary Figure S2 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S2 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S2 A. Bulk RNA-sequencing data from MOC22 tumors harvested on day 17, and MOC1 and MOC1-esc1 tumors harvested on day 14 post implantation are shown for indicated genes as z-score. (n=3 for each model.) B. qPCR data of Xcr1 from in v…
View article: Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S5 A, B. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 tumors harvested on day 16 post tumor inoculation. Number of cells per tumor mg are shown. (n=6 for esc1_Ctrl, n=8 for esc1_CCL5, representative data of two indepe…
View article: Supplementary Figure S1 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S1 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S1 A. Xcr1+ DCs in DLNs of MOC1P-ova/MOC1esc1-ova harvested 10 days post inoculation were analyzed by flow cytometry. Total number of cells per LN and number of cells per 10,000 CD45+ cells are shown. (n=5, representative data of tw…
View article: Supplementary Figure S4 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S4 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S4. A. Heatmap of CXC chemokines ligands (CXCL) based on pretreatment bulk RNA-seq data between responders and non-responders. B. CCL5 expression in each MOC model cultured media with or without IFN-γ stimulation (100U/ml for 48 hou…
View article: Supplementary Figure S3 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S3 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S3 A. Representative flow cytometry results of isolated Xcr1+ cDC1s used for DC vaccine experiments. B. Histogram of indicated marker expression gated on Xcr1+ cDC1s analyzed by flow cytometry. Xcr1+ cDCs were isolated and cultured …
View article: Supplementary Figure S4 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S4 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S4. A. Heatmap of CXC chemokines ligands (CXCL) based on pretreatment bulk RNA-seq data between responders and non-responders. B. CCL5 expression in each MOC model cultured media with or without IFN-γ stimulation (100U/ml for 48 hou…
View article: Supplementary Figure S2 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S2 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S2 A. Bulk RNA-sequencing data from MOC22 tumors harvested on day 17, and MOC1 and MOC1-esc1 tumors harvested on day 14 post implantation are shown for indicated genes as z-score. (n=3 for each model.) B. qPCR data of Xcr1 from in v…
View article: Supplementary Figure S3 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S3 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S3 A. Representative flow cytometry results of isolated Xcr1+ cDC1s used for DC vaccine experiments. B. Histogram of indicated marker expression gated on Xcr1+ cDC1s analyzed by flow cytometry. Xcr1+ cDCs were isolated and cultured …
View article: Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S5 A, B. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 tumors harvested on day 16 post tumor inoculation. Number of cells per tumor mg are shown. (n=6 for esc1_Ctrl, n=8 for esc1_CCL5, representative data of two indepe…
View article: Supplementary Figure S1 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Supplementary Figure S1 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Figure S1 A. Xcr1+ DCs in DLNs of MOC1P-ova/MOC1esc1-ova harvested 10 days post inoculation were analyzed by flow cytometry. Total number of cells per LN and number of cells per 10,000 CD45+ cells are shown. (n=5, representative data of tw…
View article: Data from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Data from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Purpose:Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resistan…
View article: Data from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Data from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Purpose:Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resistan…
View article: Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer Open
Purpose: Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resista…
View article: Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer Open
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti–programmed cell death protein 1 (PD-1) immunotherapy results …
View article: Resident memory T cell precursors in tumor draining lymph nodes require type-1 IFN for optimal differentiation
Resident memory T cell precursors in tumor draining lymph nodes require type-1 IFN for optimal differentiation Open
Resident memory (Trm) cells play an essential role in anti-tumor immunity. However, little is known about the precursors that differentiate into protective Trm populations against cancer. Here we employed an established model of B16 melano…
View article: Data from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Data from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors Open
Chimeric-antigen receptor (CAR) T-cell therapy has shown remarkable efficacy against hematologic tumors. Yet, CAR T-cell therapy has had little success against solid tumors due to obstacles presented by the tumor microenvironment (TME) of …
View article: Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors Open
Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
View article: Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy Open
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
View article: Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy Open
Activation of the stimulator of interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding of the mechanism of action of STING agonists in human tumors is k…
View article: Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors Open
Supplementary Figure from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
View article: Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy Open
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
View article: Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy Open
Activation of the stimulator of interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding of the mechanism of action of STING agonists in human tumors is k…
View article: Data from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Data from Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors Open
Chimeric-antigen receptor (CAR) T-cell therapy has shown remarkable efficacy against hematologic tumors. Yet, CAR T-cell therapy has had little success against solid tumors due to obstacles presented by the tumor microenvironment (TME) of …
View article: 503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma Open
Background Pre-operative immunotherapy results in pathologic tumor responses (pTR) for some patients with head and neck squamous cell carcinoma (HNSCC), but response mechanisms remain poorly defined.1,2 We evaluated T cell profiles and clo…
View article: 329 Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment to universally reduce solid tumors
329 Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment to universally reduce solid tumors Open
Background CAR T cell efficacy against solid tumors is challenged by key obstacles present within the tumor microenvironment (TME). These include tumor-intrinsic expression of inhibitory ligands that induce T cell exhaustion, the heterogen…
View article: Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors Open
Chimeric-antigen receptor (CAR) T-cell therapy has shown remarkable efficacy against hematologic tumors. Yet, CAR T-cell therapy has had little success against solid tumors due to obstacles presented by the tumor microenvironment (TME) of …